<DOC>
	<DOC>NCT01107340</DOC>
	<brief_summary>This is a multicentre post-marketing prospective study to evaluate performance and clinical outcomes of AMIIStem primary hip system.</brief_summary>
	<brief_title>AMIStem Primary Hip System Prospective Post-marketing Multi-centre Surveillance Study</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Hip Dislocation</mesh_term>
	<mesh_term>Hip Dislocation, Congenital</mesh_term>
	<criteria>Patient is a good candidate for a primary hip arthroplasty using AMIStem Hip System Patient is willing and able to give informed consent to participate in the followup program Patient is suitable for surgery and able to participate in the followup program. Those presenting with disease that meets the indication for use for Medacta implants defined in the study (onlabel use) Acute systemic or chronic infection Skeletal immaturity Severe muscular, neurological, vascular deficiency or other pathologies of the affected limb that may compromise the stability of the implant. Bone condition that may compromise the stability of the implant. Patient who are unwilling or unable to give consent, or to comply with the protocol and the followup program.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>